Snorkel AI Heads Into 2023 With Record Momentum and Growth
18.1.2023 17:00:00 EET | Business Wire | Press release
Snorkel AI, the data-centric AI platform company, today announced record 2022 business momentum, led by triple-digit customer growth. New customer additions included BNY Mellon, Black Swan Data, Georgetown University's Center for Security and Emerging Technology (CSET), and Pixability. Snorkel AI also added five out of the top ten US banks to its customer portfolio and expanded its roster to include a number of government agencies and Fortune 500 companies across financial services, insurance, pharma and healthcare, manufacturing and retail industries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230118005384/en/
Snorkel AI Heads Into 2023 With Record Momentum and Growth (Graphic: Business Wire)
Enterprise data science and machine learning teams use Snorkel Flow, the company’s flagship AI platform powered by programmatic labeling, to accelerate AI application development by 10-100x. Organizations achieve hundreds of thousands to over million dollars in return on investment per project, and unlock net-new use cases for NLP, document processing, automation, analytics, and more blocked by manual labeling.
“The rate of progress in AI is accelerating, especially with foundation models,” said Alex Ratner, CEO and co-founder, Snorkel AI. “However, more enterprises than ever before are effectively blocked by the training data needed to adapt models for their specific use cases and production quality requirements. With our data-centric AI platform, we bridge the gap between enterprise AI and the latest innovations. Our market leadership and growth are clear indicators of the value this unlocks for our customers.”
Snorkel AI continued to innovate in 2022 by announcing the general availability of Snorkel Flow. The company also added a number of data-centric AI capabilities designed to accelerate enterprise AI development with automated labeling, efficient collaboration between data scientists and subject matter experts, and rapid, model-guided iteration.
- Data-centric Foundation Model Development: Workflows to fine-tune foundation models or large language models and use them to build smaller, specialized models deployable for complex, performance-critical enterprise use cases.
- Continuous Model Feedback: Automated model training and integrated analysis to provide near real-time guidance when developing training data.
- Cluster View: Instant creation of embedding-based clusters and auto-generated cluster labeling functions to quickly turn a massive unlabeled dataset into high-quality training data.
- New Studio: Support for a wide range data types and ML tasks such as text and document classification and extraction, PDF and conversational AI pipelines, sequence tagging, and more.
Additional 2022 highlights included:
- Expanded Partnership Ecosystem: Snorkel AI deepened partnerships across the enterprise AI ecosystem including Microsoft Azure AI Services, Google BigQuery and Vertex AI, Snowflake, Aimpoint Digital, Four Inc. and more.
- Hosted Largest Data-Centric AI Conference: Future of Data-Centric AI 2022 brought together thousands of leaders of data science and analytics teams, AI/ML practitioners, researchers, and students. The three-day event featured over 50 sessions from Apple, AstraZeneca, CIA, Capital One, Comcast, Databricks, Ford, Google, JPMorgan Chase, Meta, NVIDIA, Orange, State Farm, and more.
- Published Breakthrough Research: Snorkel AI Research published over 30 papers at NeurIPS, ICLR, ACL and more with academic partners at Brown University, Stanford University, University of Washington, and University of Wisconsin-Madison. The research team also contributed to major initiatives such as the WRENCH benchmark and BigScience advancing the state-of-the-art for data-centric AI.
- Received Industry and Analyst Recognition: Snorkel AI was named a 2022 Cool Vendor in their AI Core Technologies report and ranked in CBInsights AI 100: Most Promising AI Startups 2022. The company was also recognized by VentureBeat for their AI innovation award for Applied AI. Additionally, Snorkel AI was featured in WingVC: Top 30 Enterprise Tech and CRN: Top 10 Hottest AI Startups and Emerging Vendors lists.
About Snorkel AI
Founded by a team spun out of the Stanford AI Lab, Snorkel AI makes AI application development fast and practical by unlocking the power of machine learning without the bottleneck of manually-labeled training data. Snorkel Flow is the first data-centric AI platform powered by programmatic labeling. Backed by Addition, Greylock, GV, In-Q-Tel, Lightspeed Venture Partners and funds and accounts managed by BlackRock, the company is based in Palo Alto. For more information on Snorkel AI, please visit: https://www.snorkel.ai/ or follow @SnorkelAI.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230118005384/en/
Contact information
Media Contact
Ignacio Ramirez
ignacio.ramirez@snorkel.ai
415-517-6708
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC3.8.2026 04:00:00 EEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that First Plus Asset Management (FPAM), a multi-asset investment management firm, has selected SS&C to provide cross-border operations support across Asia. SS&C will service First Plus across the full investment lifecycle, delivering a scalable, integrated solution supporting transfer agency, order management and execution and investment accounting. FPAM will utilize SS&C to service its growing cross-border operating model and support around $200 million in assets under management*. “As First Plus has expanded, managing our operations has become increasingly complex,” said Jeb Li, Co-Founder and CEO at First Plus. “SS&C’s global footprint and integrated offerings enable us to easily optimize our workflows, so we can focus on scaling quickly and securely while continuing to deliver risk-adjusted returns and best-in-class client service.” The engagement highlights the breadth and scalability of SS&C’s global service model.
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 11:01:00 EEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom